Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 11—November 2015
Research

Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010–2013

Kimiko UbukataComments to Author , Naoko Chiba, Shigeo Hanada, Miyuki Morozumi, Takeaki Wajima, Michi Shouji, Satoshi Iwata, and Invasive Pneumococcal Diseases Surveillance Study Group
Author affiliations: Keio University School of Medicine, Tokyo, Japan (K. Ubukata, N. Chiba, M. Morozumi, S. Iwata); Toranomon Hospital, Tokyo (S. Hanada); Tokyo University of Pharmacy and Life Sciences, Tokyo (T. Wajima); National Cancer Center Hospital, Tokyo (M. Shouji)

Main Article

Table 4

Pneumococcal serotypes by type of invasive pneumococcal diseases in adults, Japan, April 2010–March 2013*

Serotype Pneumonia, no. (%), n = 375 Bacteremia and sepsis, no. (%), n = 172 Meningitis, no. (%), n = 127 Others, no. %, n = 41 Total, no. (%), n = 715 p value†
PCV7 serotypes
4 25 (6.7) 8 (4.7) 5 (3.9) 0 38 (5.3) 0.403
6B 42 (11.2) 20 (11.6) 11 (8.7) 4 (9.8) 77 (10.8) 0.667
9V 10 (2.7) 3 (1.7) 0 0 13 (1.8) 0.161
14 36 (9.6) 9 (5.2) 6 (4.7) 3 (7.3) 54 (7.6) 0.076
18C 1 (0.3) 1 (0.6) 1 (0.8) 0 3 (0.4) ND
19F 14 (3.7) 9 (5.2) 4 (3.1) 2 (4.9) 29 (4.1) 0.617
23F 16 (4.3) 7 (4.1) 15 (11.8) 5 (12.2) 43 (6.0) 0.004
Total
144 (38.4)
57 (32.6)
42 (32.3)
14 (34.1)
257 (35.5)
0.325
Additional PCV13 serotypes
3 84 (22.4) 17 (9.9) 7 (5.5) 6 (14.6) 114 (15.9) <0.001
6A 7 (1.9) 9 (5.2) 4 (3.1) 1 (2.4) 21 (2.9) 0.101
7F 10 (2.7) 2 (1.2) 2 (1.6) 0 14 (2.0) 0.463
19A 32 (8.5) 9 (5.2) 3 (2.4) 2 (4.9) 46 (6.4) 0.035
Other‡ 0 3 (1.7) 0 0 3 (0.4) ND
Total
277 (73.9)
97 (56.4)
58 (45.7)
23 (56.1)
455 (63.6)
<0.001
Additional PPSV23 serotypes
10A 6 (1.6) 8 (4.7) 11 (8.7) 4 (9.8) 29 (4.1) 0.001
11A 10 (2.7) 3 (1.7) 3 (2.4) 0 16 (2.2) 0.798
15B 4 (1.1) 4 (2.3) 2 (1.6) 2 (4.9) 12 (1.7) 0.533
22F 20 (5.3) 12 (7.0) 12 (9.4) 3 (7.3) 47 (6.6) 0.269
Other§ 6 (1.6) 4 (2.3) 6 (4.7) 1 (2.4) 17 (2.4) 0.139
Total¶
316 (84.3)
119 (69.2)
88 (69.3)
32 (78.0)
555 (77.6)
<0.001
Nonvaccine serotypes
6C 21 (5.6) 10 (5.8) 7 (5.5) 4 (9.8) 42 (5.9) 0.994
15A 5 (1.3) 9 (5.2) 9 (7.1) 1 (2.4) 24 (3.4) 0.003
15C 1 (0.3) 4 (2.3) 3 (2.4) 0 8 (1.1) ND
23A 2 (0.5) 7 (4.1) 8 (6.3) 1 (2.4) 18 (2.5) <0.001
35B 7 (1.9) 9 (5.2) 4 (3.1) 2 (4.9) 22 (3.1) 0.101
38 6 (1.6) 1 (0.6) 1 (0.8) 0 8 (1.1) ND
Other# 7 (1.9) 4 (2.3) 3 (2.4) 0 14 (2.0) 0.918
Total
49 (13.1)
44 (25.6)
35 (27.6)
8 (19.5)
136 (19.0)
<0.001
Nontypeable** 3 (0.8) 0 0 0 3 (0.4)

*ND, not determined because of low number of strains. PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
†Significant difference obtained by comparing pneumonia, sepsis, and meningitis.
‡Serotypes 1 and 5.
§Serotypes 12F, 20, and 33F.
¶Serotype 6A is not included in PPSV23.
#Serotypes 6D, 7C, 16F, 18B, 24F, 34, and 37.
**Serotypes that were excluded from the statistical analysis because they were unclassifiable.

Main Article

Page created: October 16, 2015
Page updated: October 16, 2015
Page reviewed: October 16, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external